IRIS
CONTEDUCA, VINCENZA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.817
NA - Nord America 2.694
AS - Asia 2.517
SA - Sud America 1.089
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 9.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.580
IE - Irlanda 1.083
SG - Singapore 1.002
BR - Brasile 891
RU - Federazione Russa 699
VN - Vietnam 435
HK - Hong Kong 431
CN - Cina 327
SE - Svezia 272
IT - Italia 230
FR - Francia 165
DE - Germania 110
AR - Argentina 73
BD - Bangladesh 69
GB - Regno Unito 58
IN - India 48
FI - Finlandia 47
MX - Messico 44
CA - Canada 41
UA - Ucraina 38
EC - Ecuador 35
ID - Indonesia 33
CO - Colombia 26
AE - Emirati Arabi Uniti 24
IQ - Iraq 24
NL - Olanda 23
TR - Turchia 23
ZA - Sudafrica 19
PL - Polonia 18
AT - Austria 15
PY - Paraguay 15
VE - Venezuela 14
JP - Giappone 12
CL - Cile 11
ES - Italia 11
PE - Perù 11
UZ - Uzbekistan 11
MA - Marocco 10
PK - Pakistan 10
SA - Arabia Saudita 10
UY - Uruguay 10
DO - Repubblica Dominicana 9
EG - Egitto 8
NP - Nepal 7
BE - Belgio 6
NO - Norvegia 6
PH - Filippine 6
DZ - Algeria 5
LT - Lituania 5
OM - Oman 5
SK - Slovacchia (Repubblica Slovacca) 5
SY - Repubblica araba siriana 5
AZ - Azerbaigian 4
CR - Costa Rica 4
KE - Kenya 4
LB - Libano 4
TN - Tunisia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AU - Australia 3
ET - Etiopia 3
GR - Grecia 3
JM - Giamaica 3
JO - Giordania 3
MD - Moldavia 3
MY - Malesia 3
NI - Nicaragua 3
RO - Romania 3
TW - Taiwan 3
AL - Albania 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
LY - Libia 2
MK - Macedonia 2
PR - Porto Rico 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BB - Barbados 1
BZ - Belize 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GH - Ghana 1
GP - Guadalupe 1
HN - Honduras 1
HU - Ungheria 1
KH - Cambogia 1
KI - Kiribati 1
KW - Kuwait 1
LV - Lettonia 1
Totale 9.177
Salva come PNG Salva come JPEG
Città #
Dublin 1.081
San Jose 834
Hong Kong 429
Singapore 408
Ashburn 233
Nyköping 208
Ho Chi Minh City 165
Santa Clara 160
Chandler 146
Lauterbourg 137
Princeton 128
Wilmington 126
Dallas 117
Hanoi 84
São Paulo 82
Beijing 64
The Dalles 58
Munich 51
Moscow 34
New York 30
Helsinki 26
Des Moines 24
Belo Horizonte 23
Los Angeles 23
Da Nang 21
Rio de Janeiro 21
Nuremberg 20
London 18
Brasília 17
Jacksonville 17
Quito 17
Milan 16
Turku 16
Shanghai 15
Warsaw 15
Mexico City 14
Curitiba 13
Guarulhos 13
Rome 13
Thái Bình 13
Brooklyn 12
Buenos Aires 12
Frankfurt am Main 12
Porto Alegre 12
Guangzhou 11
Hillsboro 11
Martina Franca 11
Nanjing 11
Orem 11
Salvador 11
Bari 10
Can Tho 10
Haiphong 10
Ninh Bình 10
Nocera Inferiore 10
Tashkent 10
Atlanta 9
Biên Hòa 9
Campinas 9
Chennai 9
Chicago 9
Dhaka 9
Johannesburg 9
Norwalk 9
Ribeirão Preto 9
San Francisco 9
Tokyo 9
Trento 9
Goiânia 8
Montevideo 8
Thái Nguyên 8
Wuhan 8
Ankara 7
Boston 7
Buffalo 7
Caxias do Sul 7
Dearborn 7
Formosa 7
Fortaleza 7
Hortolândia 7
Hải Dương 7
Itaquaquecetuba 7
Lima 7
Lấp Vò 7
Madrid 7
Montreal 7
Mumbai 7
Potenza 7
Stockholm 7
Toronto 7
Amsterdam 6
Canoas 6
Garden City 6
Guayaquil 6
Manaus 6
Manchester 6
Paris 6
Pune 6
Recife 6
Seattle 6
Totale 5.430
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of HCV-Related cryoglobulinemic vasculitis: molecular, immunological and clinical analysis 166
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 116
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. 104
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 98
T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. 94
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 94
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 92
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 91
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease 91
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. 87
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation 85
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. 85
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia 85
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. 84
Androgen receptor signaling pathways as a target for breast cancer treatment 84
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 84
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study 83
Association among metabolic syndrome, inflammation, and survival in prostate cancer 83
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 82
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma 80
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients 80
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? 78
Clinical features of neuroendocrine prostate cancer 77
AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer 76
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 75
Epigenetics in prostate cancer: clinical implications 75
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide 74
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 73
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 73
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer 73
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. 73
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents 73
H. pylori infection and gastric cancer: State of the art (Review) 73
Barrett's esophagus and esophageal cancer: An overview 73
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 73
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. 72
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test 72
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 72
Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis 71
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 70
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer 70
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. 70
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. 69
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. 69
Barrett's esophagus and esophageal cancer: An overview 69
Plasma AR and abiraterone-resistant prostate cancer 69
Biological Evolution of Castration-resistant Prostate Cancer 68
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 68
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. 67
Metabolic syndrome as a peculiar target for management of prostate cancer patients 67
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 66
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network 65
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 65
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. 64
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 63
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31 63
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer 63
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy 63
The prostatic inflammation score and risk of biochemical recurrence following radical prostatectomy 62
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. 62
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 62
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis 62
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 61
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone 61
TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells 60
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. 60
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 60
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. 60
Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview 60
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. 58
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis 58
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer 58
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis 57
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes 57
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis 56
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer 55
The potential use of urine cell free DNA as a marker for cancer 55
High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer 55
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 55
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 54
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 53
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 53
Cell-free DNA as a diagnostic marker for cancer: Current insights 53
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. 53
Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications 53
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 52
Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: A 15-year prospective study 52
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy 52
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 52
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group 51
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. 51
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer 51
Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme 51
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study 51
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer 51
Immunotherapy for prostate cancer: Where we are headed 50
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 50
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 50
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 50
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 50
Totale 6.859
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.999
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.999
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 0 3
2021/2022856 4 2 3 1 371 15 25 50 102 104 17 162
2022/20231.723 186 31 86 25 47 109 3 71 1.117 15 19 14
2023/2024222 11 19 11 19 26 77 1 21 8 7 1 21
2024/20252.162 103 68 11 30 61 257 223 100 591 206 247 265
2025/20264.682 245 458 619 1.028 142 121 778 441 372 286 133 59
Totale 9.784